Annual Report

Overview

The report presents Biogen's 2023 total revenue of $9,835.6 million and approximately 7,570 employees worldwide. It highlights four FDA approvals and the acquisition of Reata, which added SKYCLARYS to its rare-disease portfolio. The ESG section states that the Board reviews ESG strategy annually and that the Executive Committee oversees actions to limit climate impacts. It also reports that women held 48.6% of director-level-and-above positions globally.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2023
Period: Ends 31 December 2023
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Standards

Other

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services